Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers

被引：101

作者：

Duda, Dan G.

Jain, Rakesh K.

Willett, Christopher G.

机构：

[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA

[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 26期

关键词：

D O I：

10.1200/JCO.2007.11.3985

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.

引用

页码：4033 / 4042

页数：10

共 65 条

[51] ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage [J].

Roy, R ;

Wewer, UM ;

Zurakowski, D ;

Pories, SE ;

Moses, MA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (49) :51323-51330

[52] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[53] A systems approach to cancer therapy (antiangiogenics plus standard cytotoxics->mechanism(s) of interaction) [J].

Teicher, BA .

CANCER AND METASTASIS REVIEWS, 1996, 15 (02) :247-272

[54] Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors [J].

Tong, RT ;

Boucher, Y ;

Kozin, SV ;

Winkler, F ;

Hicklin, DJ ;

Jain, RK .

CANCER RESEARCH, 2004, 64 (11) :3731-3736

[55] Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma [J].

Vredenburgh, James J. ;

Desjardins, Annick ;

Herndon, James E., II ;

Dowel, Jeannette M. ;

Reardon, David A. ;

Quinn, Jennifer A. ;

Rich, Jeremy N. ;

Sathornsumetee, Sith ;

Gururangan, Sridharan ;

Wagner, Melissa ;

Bigner, Darell D. ;

Friedman, Allan H. ;

Friedman, Henry S. .

CLINICAL CANCER RESEARCH, 2007, 13 (04) :1253-1259

[56] Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer [J].

Wedam, SB ;

Low, JA ;

Yang, SX ;

Chow, CK ;

Choyke, P ;

Danforth, D ;

Hewitt, SM ;

Berman, A ;

Steinberg, SM ;

Liewehr, DJ ;

Plehn, J ;

Doshi, A ;

Thomasson, D ;

McCarthy, N ;

Koeppen, H ;

Sherman, M ;

Zujewski, J ;

Camphausen, K ;

Chen, H ;

Swain, SM .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) :769-777

[57] Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II [J].

Wildiers, H ;

Guetens, G ;

De Boeck, G ;

Verbeken, E ;

Landuyt, B ;

Landuyt, W ;

de Bruijn, EA ;

van Oosterom, AT .

BRITISH JOURNAL OF CANCER, 2003, 88 (12) :1979-1986

[58] Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [J].

Willett, CG ;

Boucher, Y ;

Duda, DG ;

di Tomaso, E ;

Munn, LL ;

Tong, RT ;

Kozin, SV ;

Petit, L ;

Jain, RK ;

Chung, DC ;

Sahani, DV ;

Kalva, SP ;

Cohen, KS ;

Scadden, DT ;

Fischman, AJ ;

Clark, JW ;

Ryan, DP ;

Zhu, AX ;

Blaszkowsky, LS ;

Shellito, PC ;

Mino-Kenudson, M ;

Lauwers, GY .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8136-8139

[59] PET concerns in bevacizumab treatment - Reply [J].

Willett, CG ;

Duda, D ;

Fischman, A ;

Jain, RK .

NATURE MEDICINE, 2004, 10 (06) :561-561

[60] Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [J].

Willett, CG ;

Boucher, Y ;

di Tomaso, E ;

Duda, DG ;

Munn, LL ;

Tong, RT ;

Chung, DC ;

Sahani, DV ;

Kalva, SP ;

Kozin, SV ;

Mino, M ;

Cohen, KS ;

Scadden, DT ;

Hartford, AC ;

Fischman, AJ ;

Clark, JW ;

Ryan, DP ;

Zhu, AX ;

Blaszkowsky, LS ;

Chen, HX ;

Shellito, PC ;

Lauwers, GY ;

Jain, RK .

NATURE MEDICINE, 2004, 10 (02) :145-147

← 1 2 3 4 5 6 7 →